Patients not taking a previously prescribed bone active medication now prescribed medication through Ontario FLS

Osteoporos Int. 2022 Nov;33(11):2435-2440. doi: 10.1007/s00198-022-06446-3. Epub 2022 Jun 28.

Abstract

In an Ontario fracture liaison service (FLS), we compared medication prescription rates among patients not taking a previously prescribed bone active medication to those with no previous prescription. Prescription rates were similar between these two groups of patients. The FLS provided a secondary opportunity for patients to initiate bone active medication.

Purpose: We compared bone active medication prescription rates among patients presenting to an Ontario fracture liaison service (FLS) who reported not taking a previously prescribed bone active medication to those with no history of prescription.

Methods: Eligible patients were those screened in 39 fracture clinics between July 1, 2017, and September 15, 2019, who were not taking bone active medication at the time of screening and classified as high risk for future fracture based on CAROC or FRAX. Sociodemographic and clinical risk factor variables were assessed at screening. Bone active medication prescription rate was assessed within 6 months of screening and defined as having received a prescription for the medication from either a specialist or primary care provider. In cases where a specialist report was not available, patient self-reported data were collected. The chi-square test of independence was used to assess differences in prescription rates.

Results: Of 17,575 patients screened, eligible patients were 350 with a previous prescription and 2644 without a previous prescription. Compared with patients who reported no previous prescription, those who had a previous prescription were older, more likely to be female and to report a previous fracture, and less likely to smoke. There was no statistically significant difference between the medication prescription rate of patients with a previous prescription (73.7%) compared to patients with no previous prescription (70.7%) (p = 0.157).

Conclusion: A large jurisdiction-wide FLS approach provided a secondary opportunity to patients who were not taking a previously prescribed bone active medication to initiate that medication.

Keywords: Fracture liaison service; Fracture risk; Fragility fracture; Medication adherence; Medication initiation.

MeSH terms

  • Bone Density Conservation Agents* / therapeutic use
  • Female
  • Humans
  • Male
  • Ontario / epidemiology
  • Osteoporosis* / diagnosis
  • Osteoporosis* / drug therapy
  • Osteoporotic Fractures* / drug therapy
  • Osteoporotic Fractures* / epidemiology
  • Osteoporotic Fractures* / prevention & control
  • Secondary Prevention

Substances

  • Bone Density Conservation Agents